European Union’s ‘Digital Market Act’ Is Good, but for Online Users - It’s Not Good Enough
28.3.2022 14:00:00 EEST | Business Wire | Press release
Several international digital specialists have praised the EU’s Digital Market Act, but say its primary aim is to foster competition among tech companies while trying to reign in some of the tech giants. They say its primary focus is not protecting the personal information of digital users.
“The Digital Market Act definitely places some constraints on how some of these tech giants can use consumers’ personal data, but in terms of giving them control over their own personal information, it comes up short,” said Dr Paul Twomey, one of the lead authors of a report entitled Empowering Digital Citizens.
The report, culminating two-years of work, was presented at the Global Solutions Summit in Berlin, Germany on 28 March 2022. The annual conference brings together senior government officials with top-level academic researchers, NGO leaders, and international CEOs. It transforms research-based insights into policy recommendations for the Group of Seven (G7) and Group of 20 (G20) inter-governmental forums.
“The buying and selling of personal data is part of a $515 billion (USD) market,” says Professor Dennis J. Snower, the report’s other lead author. “Digital users are simply not a part of this transactional system and in many cases don’t even know that it exists, nor do they know who has their personal information or how it is being used. We want humane market dynamics to apply to all participants in the online economy.”
Under the Empowering Digital Citizens proposal, online users would be given control over who has access to the personally identifiable information they create. They can also, with the help of a representative, set the terms under which their data can be used (according to the law), and in return they need to ensure that their data is accurate and verified by trusted third parties. “Only the illicit drug market and online data aggregators refer to people as users,“ says Twomey. “These proposals transform that model. They empower a world of digital citizens able to reinforce their democratic rights and counter the forces of disinformation.”
Twomey and Snower represent the Global Initiative for Digital Empowerment (GIDE), which is made up of over 70 specialists from around the world, including policy experts, researchers, Internet technical experts, business people, security specialists and others. GIDE is an initiative of THE NEW INSTITUTE. Based in Hamburg, THE NEW INSTITUTE is an institute of advanced studies and a platform to find answers to the most pressing ecological, economic and political challenges of our time.
The two digital researchers say a major problem is that many online users of “free services” are given artificially restricted choices of either revealing large amounts of personal data (by agreeing to the terms and conditions of digital services) or being excluded from the economic and social interactions that define modern life.
The Empowering Digital Citizens initiative will make online and digital consumers part of the economic model that is currently invisible to the average consumer.
Access the report here: Empowering Digital Citizens. Access an FAQ on the initiative here: Q&A on Human-Centered Digital Governance.
Membership of the Global Initiative for Digital Empowerment is on page four of the Empowering Digital Citizens report.
About Dr. Paul Twomey: Dr. Twomey is co-lead of the Global Initiative for Digital Empowerment and Fellow and Initiative Director for Digital Governance at THE NEW INSTITUTE. He is a Fellow and Core Theme Leader for “managing information and technology in the public interest” at the Global Solutions Initiative. Twomey is also a Distinguished Fellow at the Centre for International Governance Innovation and a Commissioner of the Global Commission for Internet Governance. He is the former CEO of ICANN, the global coordination body of the Internet’s addressing system.
About Prof. Dennis J. Snower: Prof. Snower is co-lead of the Global Initiative for Digital Empowerment and is the director for the Socio-Economic Transformation programme at THE NEW INSTITUTE.. He is founder and President of the Global Solutions Initiative; Professor of Macroeconomics and Sustainability at the Hertie School, Berlin; Senior Research Fellow at the Blavatnik School of Government, Oxford; and Non-resident Fellow of Brookings Institution. He is co-lead of this project. He is Research Fellow at the Centre for Economic Policy Research (London), at IZA (Institute for the Future of Work, Bonn), and CESifo (Munich).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005498/en/
Contact information
Georg Diez
The New Institute
Hamburg
Tel: +49 40 3008 2714
press@thenew.institute
Brad White
White Paper Communications LLC
San Diego, CA USA
bradwhite@whitepaper.tv
Tel. +1.301.365.3571
Telegram: @Brad_White_SD
WhatsApp: +1.301.365.3571
Signal: +1.301.365.3571
Skype – bradrwhite
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
